New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents.
Lozano
E
E
Department of Systemic Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques, Barcelona, Spain.
Segarra
M
M
García-Martínez
A
A
Espígol-Frigolé
G
G
Hernández-Rodríguez
J
J
Cid
M C
MC
D015195:Drug Design; D013700:Giant Cell Arteritis / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D011111:Polymyalgia Rheumatica / Q000188:drug therapy / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D014409:Tumor Necrosis Factor-alpha